NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality
Rhea-AI Summary
NRx Pharmaceuticals (Nasdaq:NRXP) welcomed a Presidential Executive Order signed April 18, 2026 to accelerate approvals of psychedelic medications for depression, PTSD, and suicidality.
The company has Fast Track designation and received FDA guidance ahead of an upcoming New Drug Application for NRX-100 (preservative-free ketamine) and has applied for a Commissioner’s National Priority Voucher to support that NDA.
Positive
- Fast Track designation granted for NRX-100
- FDA guidance supports use of existing trials and Real World Evidence
- Applied for a Commissioner’s National Priority Voucher (CNPV) to support the NDA
Negative
- NRX-100 not yet approved; New Drug Application is upcoming and approval is pending
News Market Reaction – NRXP
In the Apr 20 session, NRXP gained 25.49%, reflecting a significant positive market reaction. Argus tracked a peak move of +19.9% during that session. Our momentum scanner triggered 57 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 5.0x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 15 | Neuroplastic TMS initiative | Positive | +0.8% | Launch of NRx Defense Systems pairing NRX-101 with robotic TMS for military use. |
| Apr 13 | Commercial leadership hire | Positive | +2.7% | Appointment of first Chief Commercial Officer to prepare NRX-100/NRX-101 launches. |
| Apr 06 | FDA label alignment | Positive | +2.3% | FDA preliminary alignment on labeling for preservative-free ketamine ANDA. |
| Mar 30 | AI depression tool deal | Positive | -4.6% | Partnership to deploy Emobot AI "Depression Thermometer" across clinics. |
| Mar 24 | Full-year results 2025 | Positive | +20.3% | Reported 2025 results, cash position, debt conversion, and key FDA signals. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent regulatory and strategic updates with positive tone have often seen aligned positive price reactions, with one notable divergence on a partnership AI announcement.
Over the past month, NRx reported multiple regulatory and strategic milestones. On Mar 24, full-year 2025 results highlighted $7.8M cash, reduced operating loss, and anticipated ANDA approval, with shares rising 20.34%. Subsequent news on AI-enabled depression monitoring, FDA labeling alignment for preservative-free ketamine, a new Chief Commercial Officer, and launch of NRx Defense Systems generally produced modest positive reactions. Today’s Executive Order-related news continues the theme of regulatory facilitation for NRX‑100 and related neuroplastic therapies.
Key Terms
fast track designation regulatory
new drug application regulatory
breakthrough therapy designation regulatory
real world evidence medical
transcranial magnetic stimulation medical
hyperbaric oxygen therapy medical
electroshock therapy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- President Trump signed an Executive Order: ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS on April 18, 2026.
- The order directs acceleration of research and lowered barriers to approvals of psychedelic medications to treat depression, PTSD, and suicidality.
- NRx Pharmaceuticals has been awarded Fast Track designation and recently received FDA guidance anticipating NRx’s upcoming New Drug Application for NRX-100 (preservative free ketamine) to treat depression, including bipolar depression, in patients who may have suicidal ideation.
- Suicide remains the second leading cause of death among Americans under the age of 35 and the only currently-approved treatment for suicidality in depression remains Electroshock Therapy.
WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq:NRXP) welcomes the newly-signed Executive Order: ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS, signed by President Trump on April 18, 2026. In the Order, the President notes that, “It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and reverse the crisis of serious mental illness in America.”
“We thank President Trump, Secretary Kennedy, and Commissioner Makary for their leadership and decisive action to address America’s mental health crisis, particularly the devastating toll of PTSD and suicide among our veterans,” said Jonathan C. Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals. “The Administration has lent Presidential authority to a commitment to act with urgency on behalf of patients and families who can no longer wait. NRx shares that mission and is proud to be aligned with this Administration in advancing solutions for severe depression, PTSD, and the mental health of military personnel, veterans, and first responders.”
The order directs the Commissioner of the US Food and Drug Administration to provide Commissioner’s National Priority Vouchers (CNPV) to appropriate psychedelic drugs that have received a Breakthrough Therapy designation and are in accordance with the criteria of the National Priority Voucher Program. NRx has applied for a CNPV in support of its upcoming New Drug Application for NRX-100.
The Presidential order further directs the Department of Health and Human Services and FDA to collaborate with the Department of Veterans Affairs and the Private Sector to increase clinical trial participation, data sharing, and real-world evidence generation regarding psychedelic drugs …to facilitate the timely evaluation and approval of drugs that meet standards for approval under section 505 of the Federal Food, Drug, and Cosmetic Act. This aspect of the executive order is expected to facilitate NRx’s proposed use of Real World Evidence and already-completed federally-funded clinical trials in support of drug approval. The order is consistent with recently-announced guidance from an FDA Type C meeting lead by the Deputy Director of the FDA Center for Drug Evaluation and Research and the Director of the FDA Division of Psychiatry Products.
“FDA’s supportive guidance on the use of existing clinical trials and Real World Evidence has now been amplified by a Presidential Executive Order,” continued Dr. Javitt. “This bold and practical leadership by the Administration will save lives that are needlessly lost to depression and suicidality. The neuroplastic drugs anticipated by this order, combined with treatments such as Transcranial Magnetic Stimulation and Hyperbaric Oxygen Therapy are demonstrating remarkable and revolutionary results in clinical trials and early clinical initiatives. We are anticipating an era in which severe depression, PTSD, and suicidality may be as treatable and repairable as physical trauma.”
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Brian Korb
Managing Partner, astr partners
(917) 653-5122
brian.korb@astrpartners.com
